November 25th, 2020 | 11:15 CET
Moderna, Triumph Gold, BioNTech - bet on winners!
Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.
time to read: 2 minutes
|
Author:
Stefan Feulner
ISIN:
CA8968121043 , US60770K1079 , US09075V1026
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
The long-term trend not in danger
The good news - the long-term upward trend is still intact. Since its low in autumn 2015 at USD 1,060.60, it has risen steeply, taking out the autumn high of 2012 at USD 1,923. The new all-time high of August this year, at just under USD 1,975, could not be broken in the past few weeks. Due to the short-term positive news regarding the US election and several successfully tested vaccines, the uncertainty temporarily disappeared from the market.
Yesterday, the gold price broke through a critical support zone at USD 1,825. If this slippage is sustained, the next broad support would be at USD 1,740, which should also be the target range for this correction. Both fundamentally, due to further uncertainties concerning the rising national debt and the fear of hyperinflation, we continue to expect new highs no later than 2021. Anticyclically, one should also think about first positions in mining stocks, which have also become cheaper. Opportunities exist in both the big players and in second-tier stocks.
Industry giants trust
One of these interesting opportunities is the Triumph Gold share. Triumph Gold Corp. is a growth-oriented Canadian gold exploration Company with a large land package in the mining-friendly, Yukon. The main focus is on the Freegold Mountain Project, which has an excellent infrastructure. Well-known names in the gold industry adorn the Canadian shareholder list. In addition to the Zijn Mining Fund, with 9.8%, and the industry leader Newmont Mining, with 12.8%, larger institutional investors with a share of over 40% are also represented.
Successful drilling program
In late September, Triumph Gold announced the completion of the fully-funded PR20-07 drill program. The results were far better than expected. In addition to minor trenching and reconnaissance sampling, diamond drilling was carried out at a depth of 2,068 metres. According to Jesse Halle, Vice President of Exploration, several of the reconnaissance samples collected indicate that gold mineralization is much more widespread than previously thought. As a result, the 2021 exploration program will be expanded. With USD 6 million in cash in the account, this exploration program is already secured.
Stock corrected
After the share price marked a high of CAD 0.48 in August this year, the value also corrected significantly by over 50% to CAD 0.215. Given the successful drilling results, this discount seems to be exaggerated. Triumph Gold offers enormous takeover potential due to the well-filled shareholder list.
Moderna for Europe
"The biggest medical revolution since Aspirin", Moderna boss Stéphane Bancel called the development of a vaccine against the coronavirus. For a long time, it was in the balance whether and how many doses the Europeans would get from the promising vaccine of the US manufacturer. Now the EU Commission has negotiated a framework agreement for up to 160 million doses, and the contract is to be formally sealed on Wednesday. In addition to Moderna, the EU Commission has secured up to 300 million doses from the German-American joint venture, BioNTech and Pfizer, plus 300 million doses from AstraZeneca.
So far, no corona vaccine has received European approval. The first licenses could be granted in December, according to expectations of the German government and the EU Commission. Before that, however, an examination by the European Medicines Agency (EMA) is necessary.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
